...
首页> 外文期刊>Rheumatology >Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
【24h】

Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.

机译:在加拿大魁北克,接受COX-2选择性抑制剂或非选择性非甾体抗炎药的老年患者的治疗转换和相关费用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVES: Lack of efficacy or tolerability of some non-steroidal anti-inflammatory drugs (NSAIDs) may lead to switching between non-selective NSAIDs (nsNSAIDs) and cyclooxygenase-2 (COX-2) selective inhibitors (coxibs), potentially increasing treatment costs due to additional physician visits and wastage of medication. This study assessed drug switching and associated costs among elderly chronic NSAID users. METHODS: Data for patients who filled their first prescription for a coxib or nsNSAID in 2001 were obtained from the Quebec Health Insurance Agency. Follow-up was terminated at the earliest of: 1 yr, the first day without NSAID exposure following the index filling date, or death. Patients could switch NSAIDs several times during follow-up. Person-days of exposure were categorized by the NSAID most recently dispensed: rofecoxib, celecoxib, Arthrotec(R) or non-Arthrotec (nA) nsNSAID. Cox regression models compared time to switch between groups, adjusting for patient baseline characteristics. Upon aswitch, pills remaining from the previous prescription were considered wasted. The costs of wasted pills and switch-associated physician visits were estimated. RESULTS: Throughout follow-up, patients filled 38 267 prescriptions for rofecoxib, 31 282 for celecoxib, 1108 for Arthrotec and 4388 for nA-nsNSAIDs. Adjusted hazard ratios (95% confidence interval) for switching versus nA-nsNSAIDs were: rofecoxib, 0.39 (0.35-0.44); celecoxib, 0.43 (0.38-0.48). Compared with nA-nsNSAID prescriptions, adjusted switching-related healthcare costs were 53 and 47% lower on average for rofecoxib and celecoxib prescriptions, respectively. These costs were 34% higher for Arthrotec prescriptions than for nA-nsNSAIDs. CONCLUSIONS: Compared with recipients of nsNSAIDs, coxib recipients were less likely to switch medications and had approximately half the adjusted costs for switching-related wasted resources per prescription.
机译:目的:某些非甾体类抗炎药(NSAID)的疗效或耐受性不足可能会导致非选择性NSAID(nsNSAID)与环氧合酶2(COX-2)选择性抑制剂(coxibs)之间的转换,从而可能增加治疗成本由于额外的医生拜访和药物浪费。这项研究评估了老年慢性非甾体抗炎药使用者的药物转换和相关费用。方法:从魁北克健康保险局获得2001年首次服用coxib或nsNSAID处方的患者的数据。随访最早在以下时间终止:1年,即指数填充日期后没有暴露于NSAID的第一天,否则死亡。在随访期间,患者可以多次更换NSAID。接触的人日数按最近分配的NSAID进行分类:罗非考昔,塞来昔布,Arthrotec(R)或非Arthrotec(nA)nsNSAID。 Cox回归模型比较了两组之间切换的时间,并根据患者的基线特征进行了调整。换药后,先前处方剩余的药丸被认为是浪费的。估计浪费的药丸和与转换有关的医师就诊的费用。结果:在整个随访过程中,患者填写了38 267剂罗非昔布处方药,31 282份塞来昔布处方药,1108份Arthrotec处方药和4388份nA-nsNSAIDs处方药。与nA-nsNSAID相比,调整后的危险比(95%置信区间)为:罗非昔布0.39(0.35-0.44);塞来昔布0.43(0.38-0.48)。与nA-nsNSAID处方相比,罗非考昔和塞来昔布处方的调整后与转换相关的医疗费用分别平均降低53%和47%。 Arthrotec处方的这些费用比nA-nsNSAID的费用高34%。结论:与nsNSAIDs的接受者相比,coxib接受者更换药物的可能性较小,并且每张处方的与转换相关的浪费资源的调整后成本约为一半。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号